Ignite Creation Date:
2024-05-06 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05730114
Status:
RECRUITING
Last Update Posted:
2023-02-15
First Post:
2023-02-06
Brief Title:
Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Sponsor:
University of Milano Bicocca
Organization:
University of Milano Bicocca
Study Overview
Official Title:
Platelet Aggregation in Patients Treated With P2Y12 Inhibitors and V-A ECMO for Cardiac Arrest
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PLT-ECMO
Brief Summary:
Dual Antiplatelet Therapy DAPT with acetylsalicylic acid ASA and oral P2Y12 inhibitor Clopidogrel Ticagrelor or Prasugrel is recommended in STEMI or NSTEMI patients undergoing primary Percutaneous Coronary Intervention PCI There is evidence for an increased risk of stent thrombosis after PCI despite administration of DAPT in patients resuscitated from a cardiac arrest with STEMINSTEMI who undergo primary PCI in particular for those treated with hypothermia Point of Care Aggregometry represents an emerging tool to measure platelet reactivity in patient treated with antiplatelets drugs Among patients with Acute Coronary Syndrome ACS those requiring Veno-Arterial Extracorporeal Membrane Oxygenation VA-ECMO for refractory Cardiogenic Shock or Cardiac Arrest represent a growing population burdened by more profound metabolic pharmacokinetic hemostatic and physiological alterations due to increased clinical severity and ECMO itself In addition profound platelet inhibition can result in a higher risk of bleeding complication since these patients have to be simultaneously anticoagulated with unfractioned heparin UFH and ECMO itself can cause coagulopathy We aimed to perform an observational prospective cohort study to investigate platelet reactivity in a population of ACS patients with different clinical severity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None